MARKET

CLLS

CLLS

Cellectis
NASDAQ
1.470
+0.040
+2.80%
After Hours: 1.470 0 0.00% 19:30 09/25 EDT
OPEN
1.450
PREV CLOSE
1.430
HIGH
1.480
LOW
1.415
VOLUME
37.74K
TURNOVER
--
52 WEEK HIGH
5.48
52 WEEK LOW
1.250
MARKET CAP
106.87M
P/E (TTM)
-2.2615
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CLLS last week (0914-0918)?
Weekly Report · 6d ago
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
Barchart · 09/19 18:31
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Barchart · 09/17 10:00
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Barchart · 09/16 16:50
Cellectis: An 'All Or Nothing' Pivot To In-Vivo Gene Editing Is Worth Monitoring
Seeking Alpha · 09/16 14:11
This Nu Holdings Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
Benzinga · 09/16 14:10
Starbucks initiated, Expedia downgraded: Wall Street’s top analyst calls
TipRanks · 09/16 13:45
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga · 09/16 13:10
More
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Webull offers Cellectis SA (ADR) stock information, including NASDAQ: CLLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLLS stock methods without spending real money on the virtual paper trading platform.